StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN opened at $0.33 on Friday. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74. The company has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.05 and a beta of 0.43. The company’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $0.81.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.